Aspirin-free antiplatelet strategies after percutaneous coronary interventions
P Capranzano, D Moliterno… - European Heart …, 2024 - academic.oup.com
Dual antiplatelet therapy (DAPT) with aspirin and a platelet P2Y12 receptor inhibitor is the
standard antithrombotic treatment after percutaneous coronary interventions (PCI). Several …
standard antithrombotic treatment after percutaneous coronary interventions (PCI). Several …
Personalized Approaches to Antiplatelet Treatment for Cardiovascular Diseases: An Umbrella Review
Antiplatelet therapy is the cornerstone of antithrombotic prevention in patients with
established atherosclerosis, since it has been proven to reduce coronary, cerebrovascular …
established atherosclerosis, since it has been proven to reduce coronary, cerebrovascular …
P2Y12 Inhibitor monotherapy versus conventional dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention: a meta …
WH Feng, YC Chang, YH Lin, HL Chen, CY Chen… - Pharmaceuticals, 2023 - mdpi.com
P2Y12 inhibitor monotherapy is a feasible alternative treatment for patients after
percutaneous coronary intervention (PCI) in the modern era. Clinical trials have shown that it …
percutaneous coronary intervention (PCI) in the modern era. Clinical trials have shown that it …
Application of the Academic Research Consortium High Bleeding Risk criteria in patients treated with coronary bioresorbable polymer everolimus-eluting stents …
AP Rubbio, L Testa, CA Pivato, D Regazzoli… - Cardiovascular …, 2024 - Elsevier
Background Previous studies have investigated a 1 to 6-month short dual antiplatelet
therapy (S-DAPT) after percutaneous coronary intervention (PCI) with modern drug eluting …
therapy (S-DAPT) after percutaneous coronary intervention (PCI) with modern drug eluting …
Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study
Aims Based on recent clinical data, the 2020 ESC guidelines on non-ST-elevation acute
coronary syndrome (NSTE-ACS) suggest to tailor antithrombotic strategy on individual …
coronary syndrome (NSTE-ACS) suggest to tailor antithrombotic strategy on individual …
What is optimal dual anti-platelet therapy duration after percutaneous coronary intervention?
H Shiomi, K Hasegawa, K Ono - 2024 - academic.oup.com
To prevent ischaemic events, including stent thrombosis (ST), long-term aggressive dual anti-
platelet therapy (DAPT) has been recommended for years. Over the past decade, however, it …
platelet therapy (DAPT) has been recommended for years. Over the past decade, however, it …
P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
Y Sotomi, Y Matsuoka, S Hikoso, D Nakatani… - Scientific Reports, 2023 - nature.com
It remains unknown whether the recent trend of short dual antiplatelet therapy (DAPT)
followed by P2Y12 inhibitor monotherapy can simply be applied to patients undergoing …
followed by P2Y12 inhibitor monotherapy can simply be applied to patients undergoing …